

Juan Pablo Arab

List of PR Articles by Year
in descending order

Source: [//exaly.com/author-pdf/6492389/publications.pdf](https://exaly.com/author-pdf/6492389/publications.pdf)

Version: 2025-02-01

139

PR articles

5,363

PR citations

63043

38

PR h-index

72913

68

g-index

151

documents

5935

doc citations

61829

41

h-index

7314

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Active alcohol consumption is associated with acute-on-chronic liver failure in Hispanic patients. <i>Gastroenterology & Hepatology</i> , 2024, 47, 562-573.	0.6	6
2	Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes. <i>Journal of Hepatology</i> , 2024, 80, 409-418.	3.6	81
3	From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women. <i>American Journal of Gastroenterology</i> , 2024, 119, 893-909.	0.7	31
4	Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon. <i>Current Hepatology Reports</i> , 2024, 23, 204-219.	0.7	5
5	Review article: Current indications and selection criteria for early liver transplantation in severe alcohol-associated hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 1049-1061.	3.9	8
6	Racial and ethnic disparities in alcohol-associated liver disease in the United States: A systematic review and meta-analysis. <i>Hepatology Communications</i> , 2024, 8, .	4.6	18
7	Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019. <i>Hepatology</i> , 2024, 80, 828-843.	10.3	35
8	Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy. <i>Therapeutic Advances in Gastroenterology</i> , 2024, 17, .	3.5	3
9	Active alcohol consumption is associated with acute-on-chronic liver failure in Hispanic patients. <i>Gastroenterology & Hepatology (English Edition)</i> , 2024, 47, 562-573.	0.1	0
10	A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD. <i>Seminars in Liver Disease</i> , 2024, 44, 273-286.	3.4	7
11	Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality. <i>Hepatology Communications</i> , 2024, 8, .	4.6	9
12	Review article: Oesophageal disorders in chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 60, 715-726.	3.9	6
13	Racial and ethnic disparities in the natural history of alcohol-associated liver disease in the United States. <i>Liver International</i> , 2024, 44, 2822-2833.	4.1	12
14	Comparative effectiveness of different corticosteroid regimens in severe alcohol-associated hepatitis. <i>Hepatology Communications</i> , 2024, 8, .	4.6	3
15	Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria. <i>Communications Medicine</i> , 2024, 4, .	5.1	36
16	Nonalcoholic Fatty Liver Disease in Latin America and Australia. <i>Clinics in Liver Disease</i> , 2023, 27, 301-315.	3.7	8
17	Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2124-2134.	6.3	51
18	Current and emerging therapies for alcohol-associated hepatitis. <i>Liver Research</i> , 2023, 7, 35-46.	1.5	8

#	ARTICLE	IF	PR CITATIONS
19	Early living donor liver transplantation for alcohol-associated hepatitis. <i>Annals of Hepatology</i> , 2023, 28, 101098.	1.6	19
20	A global research priority agenda to advance public health responses to fatty liver disease. <i>Journal of Hepatology</i> , 2023, 79, 618-634.	3.6	103
21	The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 764-783.	44.8	146
22	Inverse correlation between vitamin D and <scp>CRP</scp> levels in alopecia areata: A pilot study. <i>Journal of Cosmetic Dermatology</i> , 2023, 22, 3176-3180.	2.0	4
23	New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease. <i>Hepatology</i> , 2023, , .	10.3	32
24	Liver transplantation in Latin America: reality and challenges. <i>The Lancet Regional Health Americas</i> , 2023, 28, 100633.	3.0	5
25	Role of Prophylactic Antibiotics in Patients with Severe Alcohol-related Hepatitis. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 1146-1148.	2.5	3
26	Advances in the diagnosis and management of hepatorenal syndrome: insights into HRS-AKI and liver transplantation. <i>eGastroenterology</i> , 2023, 1, e100009.	2.6	7
27	Prophylactic Perioperative Terlipressin Therapy for Preventing Acute Kidney Injury in Living Donor Liver Transplant Recipients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 417-427.	2.5	7
28	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e289-e297.	6.3	40
29	LDL particle size and antioxidant HDL function improve after sustained virological response in patients with chronic HCV. <i>Annals of Hepatology</i> , 2022, 27, 100555.	1.6	4
30	Racial and Health Disparities among Cirrhosis-related Hospitalizations in the USA. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 398-404.	2.3	17
31	Sending an SOS: Healing the Liver with the Bone Marrow. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	2.3	0
32	Vaccination against <scp>COVID</scp>â€19 decreases hospitalizations in patients with cirrhosis: Results from a nationwide analysis. <i>Liver International</i> , 2022, 42, 942-944.	4.1	6
33	Current Medical Treatment for Alcohol-Associated Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1333-1348.	2.5	56
34	Alcohol Consumption: Medical Implications, the Liver and Beyond. <i>Alcohol and Alcoholism</i> , 2022, 57, 283-291.	1.8	95
35	The Mortality Index for Alcohol-Associated Hepatitis: A Novel Prognostic Score. <i>Mayo Clinic Proceedings</i> , 2022, 97, 480-490.	3.1	11
36	The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 552-559.	23.6	55

#	ARTICLE	IF	PR CITATIONS
37	Identifying Alcohol Use Disorder in Patients With Cirrhosis Reduces 30-Days Readmission Rate. <i>Alcohol and Alcoholism</i> , 2022, 57, 576-580.	1.8	13
38	Public Health Measures and Prevention of Alcohol-Associated Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1480-1491.	2.5	30
39	Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement. <i>Current Treatment Options in Gastroenterology</i> , 2022, 20, 261-278.	1.0	34
40	Early Diagnosis and Prevention of Infections in Cirrhosis. <i>Seminars in Liver Disease</i> , 2022, 42, 293-312.	3.4	34
41	SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 16, 100371.	3.0	10
42	Hepatocellular carcinoma in non-alcoholic fatty liver disease from a clinical and public health perspective. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, .	1.4	2
43	Biologics Are Effective in the Management of Inflammatory Bowel Disease Following Liver Transplantation in Combination With Antirejection Therapy. <i>Inflammatory Bowel Diseases</i> , 2022, , .	2.4	0
44	Nutrition in Alcohol-Related Liver Disease. <i>Current Hepatology Reports</i> , 2022, 21, 111-119.	0.7	0
45	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. <i>American Journal of Gastroenterology</i> , 2022, 117, 1917-1932.	0.7	15
46	Alcohol-Associated Hepatitis. <i>New England Journal of Medicine</i> , 2022, 387, 2436-2448.	44.0	200
47	Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2407-2416.e8.	6.3	99
48	The Lysophosphatidylinositol/G Protein-Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis. <i>Hepatology</i> , 2021, 73, 606-624.	10.3	55
49	Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. <i>Hepatology</i> , 2021, 73, 571-585.	10.3	72
50	The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 65-72.	23.6	123
51	Triple-Phase Computed Tomography May Replace Dual-Energy X-ray Absorptiometry Scan for Evaluation of Osteoporosis in Liver Transplant Candidates. <i>Liver Transplantation</i> , 2021, 27, 341-348.	2.6	3
52	Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. <i>Advances in Therapy</i> , 2021, 38, 2130-2158.	3.5	81
53	Pulsatile Epigastric Mass and Liver Masses in a 38-Year-Old Patient With Splenomegaly Since Childhood. <i>Gastroenterology</i> , 2021, 161, e14-e16.	1.0	0
54	XIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent in vitro and in vivo Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC. <i>Frontiers in Physiology</i> , 2021, 12, .	2.9	8

#	ARTICLE	IF	PR CITATIONS
55	Efficacy and safety of obeticholic acid in liver disease—A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101675.	1.9	32
56	Insulin resistance and liver histopathology in metabolically unhealthy subjects do not correlate with the hepatic abundance of NLRP3 inflammasome nor circulating IL-1 ^β levels. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001975.	3.7	3
57	Diagnosis of Alcohol-Associated Hepatitis. <i>Clinics in Liver Disease</i> , 2021, 25, 571-584.	3.7	8
58	COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	2.3	15
59	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. <i>Journal of Hepatology</i> , 2021, 75, 1026-1033.	3.6	128
60	Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. <i>Nature Communications</i> , 2021, 12, .	13.9	85
61	Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 451-461.	3.9	81
62	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. <i>Seminars in Liver Disease</i> , 2021, 41, 421-434.	3.4	89
63	Impact of Public Health Policies on Alcohol-Associated Liver Disease in Latin America: An Ecological Multinational Study. <i>Hepatology</i> , 2021, 74, 2478-2490.	10.3	68
64	Impact of COVID-19 on liver transplant recipients—A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 38, 101025.	8.5	68
65	Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV. <i>JAMA Network Open</i> , 2021, 4, e2120929.	6.9	24
66	Hepatitis C Virus Infection: What Are We Currently Doing in Latin America About WHO's Proposals for 2030?. <i>Clinical Liver Disease</i> , 2021, 18, 72-75.	1.5	11
67	Mineralocorticoid receptor modulation by dietary sodium influences NAFLD development in mice. <i>Annals of Hepatology</i> , 2021, 24, 100357.	1.6	13
68	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 19, 60-78.	44.8	608
69	Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 19, 45-59.	44.8	99
70	Resumen ejecutivo: Enfermedad por hígado graso no alcohólico en sujetos con diabetes mellitus tipo 2: Postura conjunta de la Asociación Chilena de Hepatología (ACHHEP) y la Sociedad Chilena de Diabetología (SOCHIDIAB). <i>Revista Medica De Chile</i> , 2021, 149, 1360-1371.	0.3	2
71	Factors Having an Impact on Relapse and Survival in Transplant Recipients With Alcohol-Induced Liver Disease. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 1153-1164.	2.1	18
72	Baveno VI and Expanded Baveno VI criteria successfully predicts the absence of high-risk gastroesophageal varices in a Chilean cohort. <i>Liver International</i> , 2020, 40, 1427-1434.	4.1	21

#	ARTICLE	IF	PR CITATIONS
73	An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist Fc652 in Patients With Alcohol-Associated Hepatitis. <i>Hepatology</i> , 2020, 72, 441-453.	10.3	174
74	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2020, 19, 674-690.	1.6	111
75	Higher Frequency of Hospital-Acquired Infections but Similar In-Hospital Mortality Among Admissions With Alcoholic Hepatitis at Academic vs. Non-academic Centers. <i>Frontiers in Physiology</i> , 2020, 11, .	2.9	7
76	Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. <i>Frontiers in Medicine</i> , 2020, 7, .	2.6	113
77	Alcohol-Related Liver Disease in Latin America: Local Solutions for a Global Problem. <i>Clinical Liver Disease</i> , 2020, 16, 187-190.	1.5	18
78	Are We Really Taking Care of Alcohol-Related Liver Disease in Latin America?. <i>Clinical Liver Disease</i> , 2020, 16, 91-95.	1.5	15
79	GIPC-Regulated IGFBP-3 Promotes HSC Migration In-Vitro and Portal Hypertension In-Vivo Through a β 1-Integrin Pathway. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 545-559.	5.7	30
80	Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165857.	4.2	39
81	Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy. <i>Cells</i> , 2020, 9, 817.	4.8	52
82	Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 584-599.	3.9	216
83	Metabolomic Biomarkers are Associated With Mortality in Patients With Cirrhosis Caused By Primary Biliary Cholangitis Or Primary Sclerosing Cholangitis. <i>Future Science OA</i> , 2020, 6, .	1.9	9
84	Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12. <i>Journal of Hepatology</i> , 2020, 73, 149-160.	3.6	60
85	Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165753.	4.2	55
86	Hospitalizations for Acute on Chronic Liver Failure at Academic Compared to Non-academic Centers Have Higher Mortality. <i>Digestive Diseases and Sciences</i> , 2020, 66, 1306-1314.	2.3	17
87	Quantitative assessment of portal hypertension with bi-parametric dual-frequency hepatic MR elastography in mouse models. <i>European Radiology</i> , 2020, 31, 2303-2311.	3.7	6
88	High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data. <i>World Journal of Gastroenterology</i> , 2020, 26, 7693-7706.	4.8	63
89	Letter: elevated liver enzymes and outcomes in COVID Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1235-1236.	3.9	0
90	Old Remedies to Heal the Liver: Novel Effects of Digoxin in Hepatic Sterile Inflammation. <i>Hepatology</i> , 2019, 69, 904-906.	10.3	2

#	ARTICLE	IF	PR CITATIONS
91	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 849-866.	2.4	41
92	Liver Dysfunction as a Novel Player in Alzheimer's Progression: Looking Outside the Brain. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, .	4.1	137
93	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. <i>Nature Communications</i> , 2019, 10, .	13.9	182
94	462 " Circulating Extracellular Vesicles and Sphingolipids Cargo are Highly Accurate Novel Biomarkers for Diagnosis of Alcoholic Hepatitis. <i>Gastroenterology</i> , 2019, 156, S-98.	1.0	3
95	Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). <i>Annals of Hepatology</i> , 2019, 18, 518-535.	1.6	108
96	Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF- β 2 Dependent Hepatic Stellate Cell Activation and Liver Fibrosis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 197-209.	5.7	73
97	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 321-350.	31.6	492
98	The evolving role of liver biopsy in non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2018, 17, 899-902.	1.6	31
99	804 - Integrin Based Angiocrine Signals Recruit Neutrophils to Drive Portal Hypertension in Congestive Hepatopathy. <i>Gastroenterology</i> , 2018, 154, S-1107.	1.0	0
100	892 - Transcriptional Dysregulation of Inflammatory Gene Networks in Alcoholic Hepatitis is Associated with Genomewide Reconfiguration of Epigenetic States. <i>Gastroenterology</i> , 2018, 154, S-1109.	1.0	1
101	Sa1460 - Extracellular Vesicle C16 Ceramide and S1P Content in Alcoholic Hepatitis Correlates with Disease Severity and Resolution. <i>Gastroenterology</i> , 2018, 154, S-1120.	1.0	2
102	Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1339.	4.5	25
103	Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017, 40, 388-394.	0.1	3
104	Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis. <i>Scientific Reports</i> , 2017, 7, .	3.5	83
105	Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. <i>Current Hepatology Reports</i> , 2017, 16, 286-292.	0.7	3
106	Fragmento sÁ©rico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcohÁ³lica en poblaci³n chilena. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 388-394.	0.6	12
107	Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. <i>Current Gastroenterology Reports</i> , 2017, 19, .	2.7	81
108	Nuevas terapias orales de acci³n directa para tratamiento de virus de hepatitis C (VHC). <i>Revista Medica De Chile</i> , 2017, 145, 1235-1242.	0.3	3

#	ARTICLE	IF	PR CITATIONS
109	Bile Acids and Portal Hypertension. <i>Annals of Hepatology</i> , 2017, 16, S83-S86.	1.6	15
110	Bile Acids in Cholestasis and its Treatment. <i>Annals of Hepatology</i> , 2017, 16, S53-S57.	1.6	42
111	Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. <i>Hepatology International</i> , 2017, 12, 24-33.	4.9	199
112	Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. <i>JCI Insight</i> , 2017, 2, .	5.4	19
113	Consenso chileno de prevención, diagnóstico y tratamiento de la diarrea asociada a <i>Clostridium difficile</i> . <i>Revista Chilena De Infectología</i> , 2016, 33, 98-118.	0.2	8
114	Aumento aislado y sostenido de aspartato aminotransferasa por presencia de macroenzimas: Caso clínico. <i>Revista Medica De Chile</i> , 2016, 144, 1078-1082.	0.3	5
115	Statins and portal hypertension: A tale of two models. <i>Hepatology</i> , 2016, 63, 2044-2047.	10.3	12
116	CD4/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: A prospective cohort study. <i>Vaccine</i> , 2016, 34, 1889-1895.	3.2	68
117	Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. <i>World Journal of Hepatology</i> , 2016, 8, 1075.	2.3	12
118	Evaluación para el aprendizaje: experiencia en un curso teórico de pregrado en medicina. <i>Revista Medica De Chile</i> , 2015, 143, 329-336.	0.3	7
119	Incorporación de paciente virtual en portafolio de estudiantes de medicina de pregrado. <i>Revista Medica De Chile</i> , 2015, 143, 175-182.	0.3	5
120	Evaluación de docentes clínicos de Postgrado: desarrollo y propiedades psicométricas del instrumento MEDUC-PG14. <i>Revista Medica De Chile</i> , 2015, 143, 1005-1014.	0.3	8
121	Black hairy tongue during interferon therapy for hepatitis C. <i>Annals of Hepatology</i> , 2015, 14, 414-415.	1.6	12
122	Gastrointestinal neuroendocrine tumor with unresectable liver metastases: an example of multimodal therapeutic approach. <i>Annals of Hepatology</i> , 2015, 14, 752-755.	1.6	5
123	Intrahepatic portal vein blood volume estimated by non-contrast magnetic resonance imaging for the assessment of portal hypertension. <i>Magnetic Resonance Imaging</i> , 2015, 33, 970-977.	1.8	6
124	Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. <i>World Journal of Gastroenterology</i> , 2014, 20, 12182.	4.8	54
125	Cetoacidosis diabética: Casuística 2008-2012, epidemiología y fisiopatología. <i>Revista Medica De Chile</i> , 2014, 142, 1267-1274.	0.3	2
126	Effects of bile acid sequestration on hepatic steatosis in obese mice. <i>Annals of Hepatology</i> , 2014, 13, 105-112.	1.6	7

#	ARTICLE	IF	PR CITATIONS
127	Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. <i>Journal of Physiology and Biochemistry</i> , 2014, 70, 667-674.	3.8	26
128	Management of <i>Helicobacter pylori</i> infection in Latin America: A Delphi technique-based consensus. <i>World Journal of Gastroenterology</i> , 2014, 20, 10969.	4.8	28
129	Hepatic encephalopathy in a liver transplant recipient with stable liver function. <i>Hepatology</i> , 2013, 57, 1672-1674.	10.3	7
130	Niveles sÃ©ricos de alanino-aminotransferasa en poblaci3n chilena: anÃ¡lisis de los resultados de la encuesta nacional de salud 2009-2010. <i>Revista Medica De Chile</i> , 2013, 141, 909-916.	0.3	0
131	Reanimaci3n cardiopulmonar bÃ¡sica: conocimiento te3rico, desempeÃ±o prÃ¡ctico y efectividad de las maniobras en mÃ©dicos generales. <i>Revista Medica De Chile</i> , 2012, 140, 73-77.	0.3	14
132	Aquaporin-1 Promotes Angiogenesis, Fibrosis, and Portal Hypertension Through Mechanisms Dependent on Osmotically Sensitive MicroRNAs. <i>American Journal of Pathology</i> , 2011, 179, 1851-1860.	3.5	68
133	Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2011, 10, 493-501.	1.6	15
134	Early warning of liver disease in diabetics. <i>Annals of Hepatology</i> , 2010, 9, 307-309.	1.6	4
135	Bacteriemia por <i>Streptococcus pyogenes</i> : Presentaci3n de un caso clÃnico con aparici3n tardÃa de neumonÃa. <i>Revista Medica De Chile</i> , 2010, 138, .	0.3	1
136	Effects of Japanese herbal medicine inchin-ko-to on endotoxin-induced cholestasis in the rat. <i>Annals of Hepatology</i> , 2009, 8, 228-233.	1.6	16
137	Mild hypothermia does not affect liver regeneration after partial hepatectomy in mice. <i>Liver International</i> , 2009, 29, 344-348.	4.1	9
138	Colorectal adenomas and MAFLD: a cross-sectional study in a hispanic screening cohort. , 0, , .		4
139	Prevention and control of risk factors in metabolic and alcohol-associated steatotic liver disease. , 0, 4, .		5